-
Apimostinel (GATE-202,
formerly NRX-1074) is an
investigational antidepressant,
acting as a
novel and
selective modulator of the NMDA receptor. It is...
-
Glycine site agonists: β-Fluoro-D-alanine ACBD ACC (ACPC) ACPD AK-51
Apimostinel (NRX-1074) B6B21 CCG D-Alanine D-Cycloserine D-Serine DHPG Dimethylglycine...
-
Glycine site agonists: β-Fluoro-D-alanine ACBD ACC (ACPC) ACPD AK-51
Apimostinel (NRX-1074) B6B21 CCG D-Alanine D-Cycloserine D-Serine DHPG Dimethylglycine...
-
Glycine site agonists: β-Fluoro-D-alanine ACBD ACC (ACPC) ACPD AK-51
Apimostinel (NRX-1074) B6B21 CCG D-Alanine D-Cycloserine D-Serine DHPG Dimethylglycine...
-
Glycine site agonists: β-Fluoro-D-alanine ACBD ACC (ACPC) ACPD AK-51
Apimostinel (NRX-1074) B6B21 CCG D-Alanine D-Cycloserine D-Serine DHPG Dimethylglycine...
-
Glycine site agonists: β-Fluoro-D-alanine ACBD ACC (ACPC) ACPD AK-51
Apimostinel (NRX-1074) B6B21 CCG D-Alanine D-Cycloserine D-Serine DHPG Dimethylglycine...
-
Glycine site agonists: β-Fluoro-D-alanine ACBD ACC (ACPC) ACPD AK-51
Apimostinel (NRX-1074) B6B21 CCG D-Alanine D-Cycloserine D-Serine DHPG Dimethylglycine...
- NMDA
receptor acting on
novel sites such as
rapastinel (GLYX-13) and
apimostinel (NRX-1074) are now
viewed for the
development of new
drugs with antidepressant...
-
Glycine site agonists: β-Fluoro-D-alanine ACBD ACC (ACPC) ACPD AK-51
Apimostinel (NRX-1074) B6B21 CCG D-Alanine D-Cycloserine D-Serine DHPG Dimethylglycine...
-
development was
terminated by
AstraZeneca in 2013. 4-Chlorokynurenine AD-1211
Apimostinel CERC-301
Diphenidine Ephenidine Esketamine Lefetamine Memantine Methoxphenidine...
